XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Net sales $ 649,729 $ 632,124 $ 1,899,025 $ 1,990,078
Cost of goods sold 293,826 296,441 862,037 929,495
Gross profit 355,903 335,683 1,036,988 1,060,583
Selling, general and administrative expense 200,440 201,199 610,042 634,576
Research and Development Expense 90,997 43,535 216,276 183,528
Segment profit (loss) 64,466 90,949 210,670 242,479
Interest expense 12,174 12,398 36,715 37,078
Foreign exchange (gains) losses, net 1,641 (1,680) (2,012) (5,280)
Marketable Securities, Unrealized (Gain) Loss (792,888) (36,425) 1,680,290 1,576,542
Other Nonoperating Income (Expense) 18,081 20,446 70,740 87,365
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 861,620 137,102 (1,433,583) (1,278,496)
(Provision) benefit for income taxes (208,448) (30,845) 305,185 291,464
Net income attributable to Bio-Rad $ 653,172 $ 106,257 $ (1,128,398) $ (987,032)
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 23.37 $ 3.65 $ (39.89) $ (33.63)
Weighted average common shares - basic 27,949 29,102 28,286 29,349
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 23.34 $ 3.64 $ (39.89) $ (33.63)
Weighted average common shares - diluted 27,985 29,223 28,286 29,349